New drug combo shows promise in shrinking liver tumors before surgery
NCT ID NCT05807776
First seen Apr 04, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This phase II trial tested whether giving the immunotherapy drug tislelizumab, alone or combined with the targeted therapy lenvatinib, before surgery could help shrink liver tumors in 36 patients with resectable hepatocellular carcinoma. The main goal was to see if at least half of the tumor would die (tumor necrosis rate ≥50%). The study also looked at survival, side effects, and whether the drugs delayed surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab and lenvatinib
What this could lead to
If successful, this approach could shrink liver tumors before surgery, potentially improving outcomes and reducing recurrence.
What could go wrong
This is a small, early-phase trial with only 36 participants. Results may not apply to all patients, and side effects from the drugs could delay surgery.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.